At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,446 enrolled
Drug / intervention
Recombinant Human Prourokinase for Injection (rhPro-UK) +1 moredrug
Likely dose
Recombinant Human Prourokinase for Injection (rhPro-UK) 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Recombinant Human Prourokinase（rhPro-UK）for Injection Versus Standard Medical Treatment for Acute Mild Ischemic Stroke (NIHSS≤5) Within 4.5 Hours After Symptom Onset
In Brief
A Phase 3 clinical trial evaluating Recombinant Human Prourokinase for Injection (rhPro-UK) and standard medical treatment for Ischemic Stroke and 2 related conditions. Completed, enrolled 1,446 participants across 89 sites.
Detailed Summary
The purpose of this study is to investigate the safety and efficacy of rhPro-UK (35mg) versus standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Mild, Thrombosis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartNov 2022
Primary CompletionMar 2024
Study CompletionJun 2024
TodayJul 2026
First PostedAug 19, 2022
Enrollment StartNov 15, 2022
Primary CompletionMar 26, 2024
Study CompletionJun 17, 2024
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 3.9 years ago
Interventions
Recombinant Human Prourokinase for Injection (rhPro-UK)drug
15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
standard medical treatmentdrug
Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.